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 Complement proteins were fi rst detected 
in the glomeruli of patients with glome-
rulonephritis more than 50 years ago. 1,2 
Th e fi rst complement pathway discovered 
was the classical pathway, which is prima-
rily activated by antibody bound to antigen. 
Early studies on the function of comple-
ment identifi ed it as a heat-labile system 
that complemented the function of immu-
noglobulin, and the system was termed 
 ‘ complement ’ because it was believed to 
play a complementary (that is, secondary) 
role in the elimination of bacteria by anti-
bodies. Th e identifi cation of complement 
proteins in the glomeruli of patients with 
immune complex glomerulonephritis, 
therefore, fi t nicely with the paradigm that 
the complement system provides a down-
stream, eff ector function in patients with 
immune complex glomerulonephritis. 
 Subsequent work revealed that three dis-
tinct pathways activate the complement 
system: the classical pathway, the alterna-
tive pathway, and the mannose-binding 
lectin pathway. Each of these pathways is 
engaged by numerous diff erent molecules. 
Th e alternative pathway can be activated 
by immunoglobulin 3 but can also be acti-
vated by other molecules, and it is continu-
ally autoactivated at a low level. 4 Our 
understanding of the alternative pathway 
was broadened by the recognition that 
in membranoproliferative glomerulo-
nephritis (MPGN) type 2 (now called 
dense deposit disease), C3 is deposited 
within glomeruli that do not display 
immune complex deposition. 5 It was also 
discovered that dense deposit disease is 
associated with C3 nephritic factors, a 
group of circulating autoantibodies that 
stabilize the alternative pathway C3 con-
vertase, thereby increasing the activation 
of this pathway. 6 Th is led to the hypothesis 
that uncontrolled alternative pathway acti-
vation, even in the absence of glomerular 
immune complexes, predisposed patients 
to MPGN type 2. 7 
 Factor H is a soluble protein that inhi-
bits alternative pathway activation by 
accelerating the decay of the alternative 
pathway C3 convertase and by serving 
as a cofactor for the inactivation of C3b. 
In recent years a number of mutations and 
polymorphisms in factor H have been 
associated with the development of seve-
ral renal diseases, further strengthening 
the link between alternative pathway 
activation and non-immune-complex dis-
eases of the kidney. Th e rapidly expanding 
literature implicating the alternative path-
way in renal injury suggested that there 
may be two modes of complement-medi-
ated injury of the kidney: classical-path-
way-mediated injury in immune complex 
diseases, and alternative-pathway-medi-
ated renal injury in patients with C3 
nephritic factors or other defects in alter-
native pathway regulation. Are these 
disease processes distinct, or merely two 
sides of the same coin? 
 Over the past several years, Jessy 
Alexander, Richard Quigg, and colleagues 
have conducted an interesting series of 
studies examining the role of factor H in 
models of immune complex glomerulone-
phritis. 8,9 Th ese studies investigate the 
role of an alternative pathway regulator in 
models of classical pathway activation. 
Because the alternative pathway can secon-
darily amplify complement activation by 
the classical pathway, it is not surprising 
that defi ciency of factor H exacerbates 
immune complex glomerulonephritis. But 
their results indicate that complement 
regulation by factor H may be more com-
plex, and more critical, than expected in 
immune complex glomerulonephritis. 
 Th e authors have used several models, 
including a murine model of serum sick-
ness in which mice are repeatedly injected 
with horse spleen apoferritin. Using the 
serum sickness model they demonstrated 
that mice with a targeted genetic deletion 
of the gene for factor H ( CFH   −  /  −   mice) 
displayed greater accumulation of immune 
complexes within the glomeruli than 
wild-type mice. 8 Th is indicates that factor 
H does not simply control the down-
stream eff ector functions of complement, 
but also plays an important role in 
processing and removing glomerular 
immune complexes. Equally interesting, 
in spite of abundant immune complex and 
C3 deposition within glomeruli, wild-type 
mice did not develop histologic glome-
rular injury, whereas the  CFH   −  /  −   mice 
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did. Th ese fi ndings suggest that classical 
pathway activation within the glomerulus 
is not sufficient to cause injury unless 
factor H is functionally absent. 
 As they report in this issue of  Kidney 
International , Alexander  et al. 10 have used 
the same model to further explore the 
mechanisms of complement-mediated 
glomerular injury. Like their previous 
work, this study contains some intuitive 
as well as some unexpected findings. 
In this model of immune complex 
glomeru lonephritis, the glomerular injury 
develops in  CFH   −  /  −   mice but not in 
 CFH   −  /  −   C5aR   −  /  −   mice, indicating that 
signaling by C5a is an important cause of 
injury. C5a has well-described proin-
fl ammatory eff ects, so this is not surpris-
ing. It is worth remembering, however, 
that disease in this model only develops 
in mice defi cient in factor H. Comple-
ment activation is often depicted as a 
linear process in which activation always 
culminates in the gene ration of C5a 
and the C5b-9 (the membrane attack 
complex). One would expect, therefore, 
that activation of the classical pathway by 
immune complexes would generate C5a 
and C5b-9. Yet the results of these two 
studies demonstrate that glome rular IgG 
immune complexes are not sufficient 
to cause C5a-mediated injury in the 
presence of functional factor H. 
 Another interesting fi nding is that the 
 CFH   −  /  −   C5aR   −  /  −   mice displayed less 
staining for glomerular IgG-containing 
immune complexes than did  CFH   −  /  −  
mice, and the level of anti-apoferritin anti-
bodies in the serum of  CFH   −  /  −   C5aR   −  /  −  
mice was lower than that in  CFH   −  /  −   mice. 
Th ese fi ndings indicate that the reduced 
immune complex deposition in  CFH   −  /  −  
 C5aR   −  /  −   mice may have been due to 
a blunted adaptive immune response 
to the injected antigen in the absence of 
C5a signaling. Analysis of the macro-
phages in the kidneys of the  CFH   −  /  −   and 
 CFH   −  /  −   C5aR   −  /  −   mice also demonstrated 
M2 (anti-infl ammatory) macrophages in 
the kidneys of the  CFH   −  /  −   C5aR   −  /  −   mice. 
Th e authors speculate that the M2 macro-
phages may facilitate renal repair, and 
C5a signaling may limit diff erentiation of 
macrophages toward the M2 phenotype. 
 On the basis of these results, it is unclear 
to what degree glomerular injury in the 
 CFH   −  /  −   mice is simply due to more exten-
sive complement activation within the 
glomerulus, or whether mice defi cient in 
factor H develop more severe disease due 
to an increased adaptive immune response 
and / or impaired clearance of immune 
complexes ( Figure 1 ). Indeed, the eff ects 
of factor H defi ciency may not even be 
limited to the kidney in this model. Com-
plement activation in the peritoneum at 
the time of immunization or within the 
spleen could aff ect the adaptive immune 
response. Future studies should help 
to clarify these mechanisms of injury. 
Nevertheless, the results of this study 
highlight the important role of C5a in the 
pathogenesis of immune complex glome-
rulonephritis, and demonstrate that factor 
H is a key determinant of C5a generation 
by glome rular immune complexes. 
 What do these results tell us about 
human disease? We know that patients 
with identifi able defects in factor H func-
tion are at risk of developing non-
immune-complex glomerular disease. 
However, most patients with immune 
complex glomerulonephritis, such as 
lupus nephritis and hepatitis C-associated 
MPGN, do not have mutations in factor 
H or C3 nephritic factors (although some 
such patients have been reported). Could 
it be that subtle diff erences in factor H 
function determine the degree of glome-
rular injury in these diseases? If so, then 
a unified process may underlie the 
pathogenesis of immune complex and 
non-immune-complex forms of glomerulo-
nephritis. Most of the current therapies 
for immune complex glomerulonephritis 
target the adaptive immune response. 
Anti-complement therapies have been 
considered for treatment of these diseases, 
but this approach is regarded as targeting 
the downstream eff ectors of injury, not the 
proximal cause of disease. On the basis of 
the studies by Quigg and colleagues, 8 – 10 it 
may be that local regulation of the alter-
native pathway, the generation of C5a, 
and possibly other immune functions of 
factor H are the key events that determine 
immune complex generation and whether 
glomerular immune complexes cause 
injury or not. If so, then anti-complement 
therapies could prove to be eff ective treat-
ments for many forms of glomerular dis-
ease, both with and without glomerular 
immune complexes. 
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 CD4   +   Th1 cells are effectors in 
lupus nephritis — but what are 
their targets ? 
 Joshua D.  Ooi 1 and  A. Richard  Kitching 1 , 2 , 3 
 Lupus nephritis involves both humoral and cellular effectors. 
Okamoto and colleagues isolated renal CD4   +   cells from lupus-prone 
mice, selecting cells expressing T-cell receptors on the basis of 
their activity. After transfecting CD4   +   cells with the relevant T-cell 
receptors, they transferred them into mice and induced more severe 
glomerulonephritis. This study supports a direct role for Th1 cells in 
lupus nephritis, although their antigenic specificity remains uncertain, 
as they did not recognize nucleosomes. 
 Kidney International (2012)  82, 947 – 949.  doi: 10.1038/ki.2012.254 
 Systemic lupus erythematosus is the pro-
totypic systemic autoimmune disease, 
in which autoreactivity to multiple self 
antigens results in infl ammatory changes 
in and around the small vessels of multiple 
organs. Frequently, systemic lupus ery-
thematosus involves the glomerulus, 
exhibiting variable histological patterns, 
with the most severe forms of lupus 
nephritis featuring necrotizing and cres-
centic glomerulonephritis. Th e glomeru-
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lus is vulnerable to injury mediated by a 
variety of immunological and metabolic 
insults. Unfortunately, lupus nephritis 
exemplifi es this paradigm — with observa-
tions in humans of multiple immuno-
globulin isotypes, diff erent complement 
components, and innate cellular eff ectors. 
In addition to these mediators, both B 
cells and T cells are found in the kidneys 
of patients with lupus nephritis. In severe 
lupus nephritis, as in other forms of 
rapidly progressive glomerulonephritis, 
CD4   +   T cells are present within glome-
ruli. 1 Given this complex and diverse 
eff ector involvement, a better understand-
ing of eff ector responses in severe lupus 
nephritis is important for making progress 
in treatments for this disease. 
 Over the years, much eff ort has been 
focused on the role of immunoglobulin 
and humoral mediators in defining 
pathogenic effector mechanisms of 
glome rulonephritis. Cellular eff ectors are 
more diffi  cult to characterize and cellu lar 
immunity more diffi  cult to study. None-
theless, both the presence of effector 
T cells in lesions and their functional rele-
vance in experimental models of glome-
rulonephritis imply a role for CD4   +   cells 
in severe forms of glomerulonephritis, in 
addition to injurious humoral mediators. 
Eff ector T-helper cells, in the form of Th 1 
cells or Th 17 cells, activate innate eff ector 
cells and may also directly affect renal 
tissues. 2,3 Studies in experimental rapidly 
progressive glomerulonephritis have 
demonstrated a functional role for eff ector 
CD4   +   cells of both Th 1 and Th 17 type, 2 – 4 
with additional T-cell activation mediated 
by intrinsic kidney cells. In lupus nephri-
tis too, evidence supports a role for CD4   +  
cells and T cell-derived cytokines, such as 
interferon-  (known to activate macro-
phages), as eff ectors. 5,6 
 Okamoto  et al. 7 (this issue) identifi ed 
activated Th 1 CD4   +   cells from kidneys of 
MRL / lpr mice with lupus nephritis, show-
ing markers of activation, and expressing 
high levels of the T-cell receptor with 
interferon-  , but not Th 2 or Th 17 cyto-
kines. By single-cell sorting and T-cell 
receptor sequencing and reconstitution, 
they were able to transfect syngeneic 
CD4   +   cells with the T-cell receptor 
derived from the intrarenal T cell. Th ese 
transfected cells proliferated  in vivo , 
migrated to the kidney, and triggered 
nephritis in recipient prenephritic MRL /
 lpr mice. Progression and mortality were 
enhanced in mice receiving the most 
pathogenic T cells. Th e antigen-specifi c 
T cells were not found generally through-
out the body, implying some organ (and 
antigen) target specifi city. Th e migration 
of T cells to the kidney resulted in increa-
sed macrophage numbers in both the 
glomerulus and the tubulointerstitium. 
Th ese fi ndings are consistent with Th  cell-
derived interferon-  assisting, directly and 
indirectly, in macrophage recruitment and 
activation. However, not all transferred 
T cells were alike — of the two speci fi cities 
transferred, one was clearly more potent 
in causing injury. 
 A particular strength of the study is the 
isolation of a CD4   +   cell from the kidney 
whose T-cell receptor and phenotype 
could be recapitulated and which then 
